The ongoing oleoylethanolamide story: Therapeutic implications in the control of obesity and its comorbidities.
The global burden of obesity continues to rise, demanding effective pharmacological strategies for individuals in whom prevention alone is insufficient. Recent incretin-based and multi-agonist therapies have delivered unprecedented weight loss, demonstrating that the simultaneous modulation of multiple metabolic pathways can optimize body weight control and improve obesity-related comorbidities.
The global burden of obesity continues to rise, demanding effective pharmacological strategies for individuals in whom prevention alone is insufficient. Recent incretin-based and multi-agonist therapies have delivered unprecedented weight loss, demonstrating that the simultaneous modulation of multiple metabolic pathways can optimize body weight control and improve obesity-related comorbidities.
What the study was
- Study design
- Review
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Br J Pharmacol
Why it surfaced
Matched watchlist topic 'Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk'. Study design: Review. Score: 8/10 (N:3, R:3, D:1, P:1).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.